Teva Loses Patent Challenge For Glaxo's Zofran
In his ruling, U.S. Judge Gregory Sleet of the U.S. District Court for the District of Delaware upheld the validity of Glaxo’s U.S. Patent No. 5,578,628 and 4,753,789.
The latest of the two method-of-use patents is set to expire in December 2006, taking into account the six-month pediatric exclusivity that Glaxo says it expects to obtain.
Glaxo said it is awaiting...
To view the full article, register now.